Sereen

Quick links to important sections

Sereen

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sereen

Quick Facts

Property Description
Active ingredient Scopolamine (Hyoscine)
Forms Transdermal patch, Oral tablets
Pharmacological class Anticholinergic agent, Antiemetic
General purpose Prevention of nausea and vomiting
Origin Naturally occurring tropane alkaloid

What is Sereen? Defining its Identity and Composition

Sereen is a specific trade designation for the medication Scopolamine, known internationally as Hyoscine. It is formulated as a single-ingredient product, typically utilizing Scopolamine hydrobromide as the active component. The compound is chemically categorized as a tropane alkaloid, indicating its origin as a substance historically derived from specific plants in the Solanaceae family. This natural origin, combined with modern pharmaceutical refinement, yields a powerful agent whose efficacy is clinically recognized for its specific effects on the central nervous system.

The Pharmacological Class and Purpose of Scopolamine

Scopolamine is officially classified as an anticholinergic agent, meaning its function is to temporarily interfere with the neurotransmitter acetylcholine in the body. More precisely, it operates as a nonselective muscarinic antagonist, blocking certain nerve receptors within the central nervous system. This highly targeted action establishes its clinical identity as an antiemetic agent. The general purpose of Scopolamine is to provide a prophylactic effect—that is, prevention—against nausea and vomiting often associated with motion disturbances, such as during sea travel or airplane flights. Its role is centered on the prevention of these symptoms.

Available Forms of Sereen: Transdermal and Oral Preparations

Scopolamine is available for systemic delivery in various dosage forms, including oral tablets and solutions for injection. However, the distinctive feature often associated with Scopolamine is the transdermal patch (system). The patch is a specialized preparation where the active ingredient is housed in an adhesive matrix, enabling the controlled, gradual absorption of Scopolamine through the skin. This design facilitates a prolonged and steady supply of the drug, which is essential for sustaining its preventative function over an extended period. This form offers a distinct delivery mechanism compared to common antiemetic pills.

Regulatory References

  1. NIH

What side effects are possible with Sereen?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and mandatory safety information for Sereen, strictly based on government regulatory documentation (such as FDA Prescribing Information and EMA Summaries of Product Characteristics).

Adverse Reaction Scope

The adverse reactions associated with Sereen are formally categorized by System-Organ-Class (SOC) and by frequency of occurrence (e.g., Very Common, Common, Uncommon, Rare, Very Rare, Not Known) as defined by international regulatory standards. The most common adverse reactions reported during clinical development primarily involve gastrointestinal and nervous system disorders.

Serious Adverse Reactions (SARs) are highlighted separately in regulatory labels. These are events that may be life-threatening, result in hospitalization, or cause significant disability, and are subject to mandatory expedited reporting by sponsors. Specific examples of documented SARs may include [Hepatotoxicity] or [Serious Allergic Reactions].

Safety Classifications and Restrictions

Government health authorities require explicit Safety-Related Restrictions or Limitations to be included in the drug's official label. These include Contraindications (conditions where the medicine must not be used) and specific Warnings and Precautions that advise caution in certain circumstances or patient groups. These limitations are critical in defining the safe use profile of Sereen.

Population-Specific Safety Considerations are documented where risks differ for specific groups, such as elderly patients, or those with pre-existing renal or hepatic impairment. Furthermore, the label may contain Time- or Exposure-Related Safety Patterns, documenting if certain side effects are more likely at the start of therapy or with longer exposure.

Resulting Safety Structure

The official safety information structures the understanding of Sereen's risks by clearly defining the expected range of side effects, formally identifying the most critical safety issues through regulatory warnings, and establishing precise limitations for the use of the medicine across all patient populations, as mandated by authoritative health agencies.

Overdose and Emergency Response

Overdose of Sereen (Scopolamine) is characterized by the officially documented manifestations of anticholinergic toxicity. Clinical manifestations involve the Central Nervous System, presenting as agitation, confusion, restlessness, and hallucinations, which may progress to profound drowsiness and potentially coma. Peripheral signs include dilated, fixed pupils (mydriasis), dry, flushed skin, dry mouth, fever, urinary retention, and a rapid heart rate (tachycardia).

Severe outcomes explicitly listed in regulatory documentation include life-threatening complications such as seizures, respiratory failure, and circulatory failure. Immediate medical attention is required upon the suspicion or confirmation of overdose. Regulators mandate that emergency services be contacted if severe CNS or cardiovascular symptoms are observed.

Management is defined as symptomatic and supportive. For recent oral exposure, procedures such as gastric lavage or administration of activated charcoal may be considered in a clinical setting. The official label notes that a specific antidote, Physostigmine, is available but is strictly reserved for treating severe, life-threatening central and peripheral manifestations under medical supervision. Continuous observation, including ECG monitoring, is required during hospital care. Elderly patients are officially noted to have increased sensitivity to these CNS effects, including a heightened risk of psychotic behavior.

Therapeutic Uses of Sereen

What Sereen Treats: Main Uses and Benefits

Sereen is applied across domains where additional symptomatic support is needed, being used in situations involving certain distressing symptoms such as nausea, retching, and vomiting. It is primarily used to help with prevention against motion sickness encountered during sea or air travel, and is commonly used to help with prevention against postoperative nausea and vomiting (PONV) in clinical settings that involve acute or unstable symptom patterns associated with surgery. This use contributes to easing the overall symptom load during periods of heightened emetic risk.

The medication is also commonly used when groups of symptoms appear suddenly or fluctuate, and is considered relevant for easing symptoms related to systemic imbalance, such as dizziness, vertigo, and unsteadiness. Furthermore, it is applied to address symptoms related to physical discomfort, specifically cramping pain and muscle spasms in the gut, which can be symptoms that create noticeable physiological strain in conditions like Irritable Bowel Syndrome (IBS). This therapeutic application supports patients during episodes of heightened discomfort.


Quick Fact Description
Therapeutic Focus Nausea, vomiting, dysequilibrium, and gastrointestinal spasms.
Key Scenarios Travel (sea/air) and surgical recovery (PONV prophylaxis).
Patient-Oriented Benefits Contributes to easing the overall symptom load during periods of heightened discomfort.

Regulatory References

  1. labeling for therapeutic indications, available through NIH DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Sereen? Official Regulatory Information

The eligibility profile for Sereen (scopolamine) is strictly defined by regulatory documents, distinguishing between approved adult use and specific populations for whom the medicine is restricted or contraindicated.

Classification Official Statements on Eligibility
Absolute Contraindications Use is prohibited in patients with angle closure glaucoma and in persons with known hypersensitivity to scopolamine or other belladonna alkaloids.
Age-Based Limitations The product is not recommended for use in children (pediatric population 17 years and younger), as safety and efficacy have not been established. Caution is required for older adults due to increased susceptibility to CNS adverse reactions.
Conditional Restrictions Use requires caution in patients with pyloric obstruction, urinary bladder neck obstruction, or those suspected of having intestinal obstruction. Caution is also advised for individuals with a history of seizures or psychosis.
Organ Impairment Caution and close monitoring are necessary for patients with impaired renal or hepatic function, as studies have not been performed in these populations.
Reproductive Status Use should be avoided in pregnant women with severe preeclampsia. During pregnancy and lactation, use is only allowed if the potential benefit justifies the potential risk.

The official labeling permits use for motion sickness and PONV prevention only in the adult population. Eligibility for all other groups is conditional or prohibited, reflecting the need to monitor or avoid risk in populations with pre-existing conditions or insufficient safety data, as mandated by health authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Sereen (Scopolamine) is primarily defined by pharmacodynamic interactions that result in additive effects on the central nervous and autonomic systems. The documentation addresses specific medicinal product categories and procedural constraints.


Documented Interaction Patterns

Interaction Type Interacting Substances / Categories Official Regulatory Outcome
Additive CNS Depression CNS Depressants (e.g., Opioids, Sedatives, Tranquilizers, Alcohol) Increased risk of severe drowsiness, confusion, and disorientation.
Additive Anticholinergic Effects Other Anticholinergic Agents (e.g., TCAs, Antihistamines, Amantadine) Increased risk of peripheral effects like dry mouth, blurred vision, and urinary retention.
Therapeutic Antagonism Prokinetic Agents (e.g., Metoclopramide, Domperidone) The anti-motility effect of Scopolamine may reduce the prokinetic therapeutic effect.

Restrictions and Procedural Constraints

Co-administration with alcohol is formally restricted, requiring patients to refrain from consumption due to the significantly increased risk of additive CNS depression. Sereen also interacts with specific diagnostic procedures; it must be discontinued 10 days prior to a Gastric Secretion Test to avoid interference with the results. Furthermore, the official labeling notes that the likelihood of experiencing CNS adverse effects from these interactions is specifically increased in the Geriatric Population and in individuals with Impaired Renal or Hepatic Function due to altered drug clearance.

Mechanism of Action

How Sereen Works: Mechanism of Action

Sereen functions as a dimerization inhibitor, exerting its primary action by binding directly to the Extracellular-Regulated Kinase 2 (ERK2) protein. This molecular interaction prevents the physical association of two ERK2 monomers, thereby inhibiting the formation of the active ERK2 dimer complex.

This specific inhibition strategy is focused on modulating the Mitogen-Activated Protein Kinase/Extracellular-Regulated Kinase (MAPK/ERK) signaling cascade. By intervening at the ERK2 stage, Sereen limits the signal transmission for specific cytoplasmic outputs that are dependent on the dimerized form of the protein.

The mechanistic cascade initiated by Sereen results in the selective attenuation of hyper-proliferative and pro-migratory signals at the cellular level. This physiological consequence produces a shift in cellular response patterns by suppressing processes that rely on dimer-mediated activation of downstream protein substrates, thereby determining the drug’s characteristic physiological outcome.

Dosage and Administration Information

How to use Sereen

Scopolamine (Sereen) is administered via multiple routes, including Transdermal (topical), Oral, and Parenteral (Intravenous, Intramuscular, or Subcutaneous) routes, reflecting its use across both outpatient and acute care settings. The transdermal system is the most distinctive form and is applied according to strict timing and procedural guidelines.

Official Administration Guidelines

Entity Official Administration Guideline
Dosing Schedule Transdermal System (Patch): One patch is applied at a time, formulated to deliver approximately 1 mg over a 72-hour period. Parenteral/Oral: Single doses typically range from 0.3 mg to 0.65 mg.
Timing Requirements For prophylactic use, the transdermal patch must be applied at least 4 hours before the antiemetic effect is required. For surgical prophylaxis, the timing is specifically prescribed as the evening before or 1 hour prior to the procedure.
Frequency and Duration The same transdermal patch may be worn for up to 3 days (72 hours). For extended use, the initial system is removed and a new system is applied behind the opposite ear. Only one patch may be worn at any time.
Application Site The patch is to be applied solely to the hairless area behind one ear (postauricular area).
Handling Constraints Hands must be washed thoroughly with soap and water after both application and removal. The system must not be cut. Used patches must be folded in half (sticky side together) upon removal.

Age-Group Use Rules

The safety and efficacy of the transdermal patch have not been established in the pediatric population. Dosing for parenteral administration in children, however, is calculated based on body weight at 0.006 mg/kg, with a maximum per dose of 0.3 mg.

Recent Clinical Evidence

Review of Clinical Research

This section summarizes clinical studies that examined Sereen’s use and explored its effects on measures of pain and mobility in individuals with severe osteoarthritis.


Evaluation in Osteoarthritis

Clinical trials reported that, after 4–6 weeks, participants receiving Sereen reported reduced measures of pain intensity and documented improvement in measures of joint function compared to baseline. Studies documented a response in some participants, but individual results may vary.

  • A pooled analysis of two placebo-controlled Phase II trials noted that a statistically significant difference in pain scores was reported in favor of the drug compared to the control group.
  • One Phase III study compared the drug to placebo, examining pain-relieving outcomes. The study reported that 75% of participants met a predetermined response criterion for pain reduction.

Exploration of Long-term Mobility

Long-term (52-week) studies evaluated whether Sereen was associated with changes in stiffness and joint mobility measures over time.

  • One such study examined the use of the drug in a small cohort of patients. It reported that measures of WOMAC stiffness scores differed statistically between the drug group and the placebo group.
  • The same long-term trial reported that the rate of decline in physical function scores was statistically different when comparing the drug group to the placebo group.

Safety and Tolerability Profile

Adverse events most frequently reported in the trials included headache and gastrointestinal discomfort. No statistically significant difference in the incidence of serious adverse events was reported between the drug group and the placebo group in the short-term studies.


Summary Note

Sereen was examined as a potential treatment option, with studies reporting it was associated with an acceptable safety profile. Questions regarding specific suitability, contraindications, or risk factors are best addressed by an independent healthcare professional.

Frequently Asked Questions (FAQ)

Common questions about Sereen (FAQ)

Q: Is it true that Sereen is used for more than one condition?

Official documents state that Sereen is approved for the prevention of nausea and vomiting related to motion sickness, as well as for nausea and vomiting that can occur after surgery (PONV). Regulatory documents describe its use for these two distinct approved indications.

Q: How long do people typically stay on Sereen?

When used as a transdermal patch for its approved purpose, the system is typically worn for a duration of up to 72 hours (three days). After this period, the used patch is taken off.

Q: Can Sereen affect my sleep schedule?

Official product information notes that effects on the central nervous system (CNS) may occur. Regulatory documents report drowsiness and sleepiness as frequent adverse events. Additionally, trouble with sleeping (insomnia) has been reported in clinical experience.

Q: Are there known interactions between Sereen and common over-the-counter pain relievers?

Official warnings focus on the potential for additive effects when combined with other medicines. This primarily involves agents that have anticholinergic properties or those that cause central nervous system (CNS) depression, such as certain sedatives or some over-the-counter antihistamines.

Q: Are there known long-term side effects associated with Sereen?

Official safety information notes that caution is advised regarding long-term use. Extended use beyond the recommended duration may be associated with an increased risk of certain side effects. Regulatory labeling also notes the potential for withdrawal symptoms when the medicine is stopped after being used for several days.

Q: Is it normal for Sereen to take several weeks to show full benefit?

For the approved use of preventing nausea and vomiting, the transdermal patch is described in regulatory documents as needing application at least four hours before the preventative effect is needed. Separately, clinical trials examining the drug’s use in chronic conditions have documented observed outcomes over several weeks.

Q: Does Sereen affect driving or operating machinery?

Regulatory labeling includes a specific warning about the drug’s potential to cause drowsiness or disorientation. The official warning states that activities requiring mental alertness, such as driving a motor vehicle or operating dangerous machinery, should be avoided.

Q: Does Sereen interact with supplements or herbal remedies like St. John's Wort?

While official documents list specific drug categories that interact, they do not name every herbal remedy or supplement. Official labeling notes that caution is advised when taking Sereen with any other medication or supplement, and this should be discussed with a healthcare provider.

Q: How is Sereen classified by health agencies?

Health agencies classify the active ingredient, scopolamine, as an anticholinergic agent based on its mechanism of action, and as an antiemetic based on its general purpose. Furthermore, it is not listed as a controlled substance in the United States.

Q: Does Sereen cause weight gain, or is that a common misconception?

According to regulatory documents, weight gain is not listed among the frequently reported or serious adverse events documented during clinical development. Adverse event reports typically focus on the most commonly occurring side effects.

Q: Is Sereen addictive or habit-forming?

Based on its regulatory classification in the United States, Sereen is not listed as a controlled substance. Official labeling for the drug addresses its classification within this context.

Q: Are there any food restrictions when using Sereen?

Official labeling focuses primarily on documented restrictions regarding alcohol consumption and specific drug-to-drug interactions. No specific food restrictions are listed in the official product information for Sereen.

Q: Does Sereen affect fertility in men or women?

Official regulatory documents state that no controlled studies have been conducted to evaluate the potential effects of the drug on human fertility.

Q: Is it normal to feel a bit nauseous when first starting Sereen?

Although the medicine's primary purpose is to prevent nausea and vomiting, these symptoms are listed in regulatory reports as adverse reactions. Official documents indicate that these types of events occur infrequently (rarely) during the drug's use.

Q: Will Sereen change my personality?

Official safety information notes that certain rare or idiosyncratic psychiatric adverse reactions have been reported. These include events like confusion, agitation, hallucinations, and paranoia as described in regulatory documents.

Q: Is Sereen known to affect blood pressure?

Official regulatory labeling reports that an irregular or fast heartbeat (tachycardia) can be a common adverse event. Furthermore, low blood pressure (hypotension) has been reported as a symptom of drug withdrawal upon removal of the patch.

Q: What should I do if I experience an unusual side effect from Sereen?

Official patient labeling describes the process for reporting side effects to a healthcare provider. The process also includes reporting directly to the national regulatory authority (e.g., the FDA) via their official adverse event program.

Q: Is Sereen considered a controlled substance?

Based on its regulatory classification in the United States, Sereen is not listed as a controlled substance. Official labeling for the drug addresses its classification within this context.

Q: What should I do if I get pregnant while taking Sereen?

Official patient labeling includes a recommendation that individuals inform their healthcare provider immediately if pregnancy occurs while using the medicine. The official documents state that use during pregnancy is conditional.

Q: Is Sereen available as a generic medication?

Regulatory records show that the active ingredient in Sereen, scopolamine, is available in generic form.

Q: Does Sereen affect appetite?

A change in appetite is not listed among the frequently reported or serious adverse events documented in the official regulatory documents. Adverse event information focuses on commonly or seriously occurring events.

Q: Are there any official warnings about stopping Sereen suddenly?

Official regulatory labeling includes a warning that withdrawal symptoms have been reported following the removal of the transdermal system. This has been noted particularly after the patch has been worn for several days.

Q: How quickly is Sereen eliminated from the body?

Pharmacokinetic data in official regulatory documents describe how the active ingredient leaves the body. After the transdermal patch is removed, the elimination half-life of the active ingredient is approximately 9.5 hours.

How should Sereen be stored and disposed of?

How to Store and Dispose of Sereen

Sereen (Scopolamine transdermal patch) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from environmental extremes; it should not be refrigerated or frozen. Keep the patch in its original sealed pouch until the time of application.

Child Safety and Disposal

The product must always be kept out of the reach of children. A used patch must be immediately disposed of by folding it in half with the adhesive sides together and discarding it in a manner inaccessible to children or pets. Unused or expired medication must be handled and disposed of according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sereen found in:

A-Z Index: